Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C | 46 | 2021 | 1521 | 4.880 |
Why?
|
Hepacivirus | 44 | 2021 | 1323 | 4.320 |
Why?
|
Hepatitis C, Chronic | 18 | 2021 | 1005 | 1.630 |
Why?
|
Hepatitis B | 8 | 2022 | 651 | 1.500 |
Why?
|
Antiviral Agents | 29 | 2022 | 2807 | 1.480 |
Why?
|
CD8-Positive T-Lymphocytes | 24 | 2022 | 4264 | 1.090 |
Why?
|
Interleukins | 3 | 2017 | 799 | 0.880 |
Why?
|
Substance Abuse, Intravenous | 9 | 2019 | 481 | 0.850 |
Why?
|
Hepatitis B, Chronic | 5 | 2022 | 346 | 0.790 |
Why?
|
HIV Infections | 22 | 2022 | 15906 | 0.790 |
Why?
|
Protease Inhibitors | 4 | 2015 | 784 | 0.760 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 259 | 0.710 |
Why?
|
Ribavirin | 8 | 2021 | 394 | 0.670 |
Why?
|
Interferons | 8 | 2020 | 677 | 0.640 |
Why?
|
Hepatitis, Viral, Human | 1 | 2017 | 133 | 0.630 |
Why?
|
Drug Resistance, Viral | 4 | 2010 | 798 | 0.610 |
Why?
|
RNA, Viral | 12 | 2013 | 2871 | 0.610 |
Why?
|
Hepatitis B virus | 7 | 2022 | 459 | 0.610 |
Why?
|
Specialization | 1 | 2020 | 788 | 0.550 |
Why?
|
Drug Users | 2 | 2013 | 114 | 0.540 |
Why?
|
HLA-B Antigens | 3 | 2011 | 383 | 0.540 |
Why?
|
Prisoners | 4 | 2013 | 279 | 0.530 |
Why?
|
Major Histocompatibility Complex | 1 | 2017 | 1020 | 0.510 |
Why?
|
Needle Sharing | 1 | 2013 | 22 | 0.510 |
Why?
|
Communicable Disease Control | 2 | 2020 | 813 | 0.500 |
Why?
|
Interferon-alpha | 5 | 2019 | 897 | 0.490 |
Why?
|
Epitopes, T-Lymphocyte | 16 | 2013 | 871 | 0.480 |
Why?
|
Viral Nonstructural Proteins | 7 | 2013 | 242 | 0.450 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2022 | 4388 | 0.400 |
Why?
|
Oligopeptides | 3 | 2015 | 1230 | 0.400 |
Why?
|
Viremia | 6 | 2012 | 726 | 0.370 |
Why?
|
HIV-1 | 7 | 2013 | 6900 | 0.370 |
Why?
|
Mass Screening | 4 | 2021 | 5219 | 0.370 |
Why?
|
HLA-B27 Antigen | 3 | 2013 | 79 | 0.320 |
Why?
|
Viral Load | 8 | 2020 | 3281 | 0.320 |
Why?
|
Polyethylene Glycols | 3 | 2009 | 1178 | 0.320 |
Why?
|
Hepatitis C Antibodies | 5 | 2013 | 140 | 0.300 |
Why?
|
Virus Replication | 6 | 2013 | 2565 | 0.300 |
Why?
|
Rheumatic Diseases | 2 | 2021 | 539 | 0.270 |
Why?
|
Immunologic Memory | 2 | 2021 | 1381 | 0.250 |
Why?
|
Humans | 93 | 2022 | 715594 | 0.250 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2007 | 661 | 0.250 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7445 | 0.240 |
Why?
|
Physicians | 1 | 2020 | 4371 | 0.230 |
Why?
|
Antigens, Viral | 2 | 2021 | 1159 | 0.210 |
Why?
|
Epitopes | 3 | 2021 | 2646 | 0.200 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2022 | 152 | 0.200 |
Why?
|
Male | 49 | 2021 | 350143 | 0.190 |
Why?
|
Cohort Studies | 16 | 2022 | 40040 | 0.190 |
Why?
|
Liver Diseases | 3 | 2020 | 1243 | 0.190 |
Why?
|
Hepatitis D | 1 | 2019 | 18 | 0.190 |
Why?
|
Immunodominant Epitopes | 3 | 2011 | 264 | 0.190 |
Why?
|
Genotype | 9 | 2017 | 12929 | 0.190 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 219 | 0.180 |
Why?
|
Aspartate Aminotransferases | 1 | 2020 | 414 | 0.180 |
Why?
|
Jaundice | 1 | 2019 | 85 | 0.180 |
Why?
|
Latent Tuberculosis | 1 | 2021 | 198 | 0.170 |
Why?
|
Acute Disease | 9 | 2017 | 7137 | 0.170 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 270 | 0.170 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2019 | 1395 | 0.160 |
Why?
|
Female | 43 | 2021 | 377052 | 0.160 |
Why?
|
Alanine | 1 | 2020 | 585 | 0.160 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3166 | 0.160 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3283 | 0.160 |
Why?
|
Infectious Disease Medicine | 1 | 2017 | 47 | 0.160 |
Why?
|
Liver | 5 | 2020 | 7588 | 0.160 |
Why?
|
Adult | 31 | 2022 | 212237 | 0.160 |
Why?
|
Middle Aged | 35 | 2022 | 214639 | 0.150 |
Why?
|
Substance-Related Disorders | 1 | 2013 | 4182 | 0.150 |
Why?
|
Immunity, Innate | 4 | 2020 | 2937 | 0.140 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 410 | 0.140 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 2189 | 0.140 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 17399 | 0.140 |
Why?
|
Cryoglobulinemia | 1 | 2015 | 86 | 0.140 |
Why?
|
Receptors, Fc | 1 | 2019 | 560 | 0.140 |
Why?
|
Piperidines | 2 | 2021 | 1580 | 0.140 |
Why?
|
Fatigue | 1 | 2022 | 1457 | 0.140 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 69 | 0.140 |
Why?
|
HLA-A Antigens | 3 | 2010 | 250 | 0.130 |
Why?
|
Interferon Type I | 1 | 2017 | 503 | 0.130 |
Why?
|
Fluorenes | 1 | 2015 | 153 | 0.130 |
Why?
|
North America | 1 | 2017 | 1202 | 0.130 |
Why?
|
Comorbidity | 5 | 2020 | 10429 | 0.120 |
Why?
|
Professional Role | 1 | 2016 | 307 | 0.120 |
Why?
|
HIV | 2 | 2019 | 1542 | 0.120 |
Why?
|
Disease Progression | 6 | 2020 | 13219 | 0.120 |
Why?
|
Homosexuality, Male | 2 | 2012 | 1155 | 0.120 |
Why?
|
Antigen Presentation | 2 | 2010 | 1251 | 0.120 |
Why?
|
Genes, MHC Class I | 2 | 2010 | 274 | 0.110 |
Why?
|
Polysaccharides | 1 | 2019 | 996 | 0.110 |
Why?
|
Phylogeny | 6 | 2009 | 2796 | 0.110 |
Why?
|
Vaccination | 2 | 2021 | 2936 | 0.110 |
Why?
|
Endocarditis | 1 | 2016 | 326 | 0.110 |
Why?
|
Seroepidemiologic Studies | 1 | 2013 | 373 | 0.110 |
Why?
|
Pyrimidines | 2 | 2021 | 2929 | 0.110 |
Why?
|
Proline | 3 | 2021 | 437 | 0.100 |
Why?
|
Suppression, Genetic | 1 | 2011 | 205 | 0.100 |
Why?
|
Mutation, Missense | 2 | 2011 | 2515 | 0.100 |
Why?
|
Young Adult | 11 | 2020 | 56140 | 0.100 |
Why?
|
Prisons | 2 | 2010 | 147 | 0.100 |
Why?
|
2-Naphthylamine | 2 | 2021 | 24 | 0.100 |
Why?
|
Europe | 1 | 2017 | 3344 | 0.100 |
Why?
|
Antigens, Surface | 2 | 2022 | 1841 | 0.100 |
Why?
|
Placenta | 1 | 2019 | 1534 | 0.100 |
Why?
|
Syphilis | 1 | 2012 | 212 | 0.100 |
Why?
|
Ritonavir | 2 | 2022 | 311 | 0.100 |
Why?
|
Benzimidazoles | 1 | 2015 | 876 | 0.100 |
Why?
|
HLA Antigens | 3 | 2011 | 1545 | 0.090 |
Why?
|
Immunity, Active | 1 | 2009 | 62 | 0.090 |
Why?
|
Killer Cells, Natural | 2 | 2019 | 2168 | 0.090 |
Why?
|
Creatinine | 1 | 2015 | 1888 | 0.090 |
Why?
|
Psychoses, Substance-Induced | 1 | 2010 | 99 | 0.090 |
Why?
|
Macrocyclic Compounds | 3 | 2019 | 70 | 0.090 |
Why?
|
Cause of Death | 1 | 2020 | 3619 | 0.090 |
Why?
|
Uracil | 2 | 2021 | 159 | 0.090 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2009 | 94 | 0.090 |
Why?
|
Remission, Spontaneous | 4 | 2013 | 389 | 0.090 |
Why?
|
Cyclopropanes | 2 | 2021 | 426 | 0.090 |
Why?
|
DNA, Viral | 3 | 2022 | 2290 | 0.090 |
Why?
|
Lactams, Macrocyclic | 2 | 2021 | 321 | 0.080 |
Why?
|
Viral Proteins | 4 | 2010 | 1959 | 0.080 |
Why?
|
Pharmacogenetics | 1 | 2012 | 700 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1863 | 0.080 |
Why?
|
Aged | 19 | 2020 | 162392 | 0.080 |
Why?
|
Tissue Donors | 1 | 2017 | 2152 | 0.080 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2544 | 0.080 |
Why?
|
Immunoassay | 2 | 2012 | 764 | 0.080 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2101 | 0.080 |
Why?
|
Immunoglobulin G | 1 | 2019 | 4490 | 0.080 |
Why?
|
Pilot Projects | 4 | 2015 | 8079 | 0.080 |
Why?
|
Survival Analysis | 2 | 2013 | 10513 | 0.080 |
Why?
|
T-Lymphocytes | 4 | 2009 | 10285 | 0.080 |
Why?
|
HLA-A3 Antigen | 1 | 2006 | 35 | 0.080 |
Why?
|
Mutation | 7 | 2011 | 29253 | 0.080 |
Why?
|
HIV Core Protein p24 | 1 | 2006 | 257 | 0.080 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2006 | 72 | 0.070 |
Why?
|
Cross Infection | 1 | 2015 | 1404 | 0.070 |
Why?
|
Epitope Mapping | 1 | 2007 | 301 | 0.070 |
Why?
|
Lymphocyte Activation | 6 | 2019 | 5859 | 0.070 |
Why?
|
Tryptophan Synthase | 2 | 1995 | 9 | 0.070 |
Why?
|
Liver Function Tests | 2 | 2020 | 535 | 0.070 |
Why?
|
Recombinant Proteins | 4 | 2009 | 6803 | 0.070 |
Why?
|
HLA-B8 Antigen | 1 | 2004 | 21 | 0.070 |
Why?
|
Meningitis, Bacterial | 1 | 2007 | 225 | 0.070 |
Why?
|
United States | 6 | 2021 | 67895 | 0.060 |
Why?
|
Lymphocyte Count | 1 | 2006 | 808 | 0.060 |
Why?
|
Lectins, C-Type | 1 | 2008 | 604 | 0.060 |
Why?
|
Psychiatry | 1 | 2016 | 1623 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2015 | 2097 | 0.060 |
Why?
|
Treatment Outcome | 9 | 2017 | 62039 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1896 | 0.060 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2004 | 83 | 0.060 |
Why?
|
Program Evaluation | 1 | 2013 | 2538 | 0.060 |
Why?
|
Alanine Transaminase | 2 | 2020 | 599 | 0.060 |
Why?
|
Interferon-gamma | 3 | 2007 | 3248 | 0.060 |
Why?
|
Disease Transmission, Infectious | 1 | 2009 | 543 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7877 | 0.060 |
Why?
|
Cross-Sectional Studies | 3 | 2021 | 23385 | 0.060 |
Why?
|
Risk Factors | 6 | 2020 | 70931 | 0.060 |
Why?
|
Temporal Bone | 1 | 2007 | 671 | 0.060 |
Why?
|
Genome-Wide Association Study | 3 | 2017 | 11956 | 0.060 |
Why?
|
Hepatitis B e Antigens | 1 | 2022 | 105 | 0.060 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2007 | 1116 | 0.060 |
Why?
|
Canada | 2 | 2021 | 1965 | 0.060 |
Why?
|
Histocompatibility Testing | 1 | 2004 | 801 | 0.060 |
Why?
|
Liver Transplantation | 1 | 2013 | 2019 | 0.050 |
Why?
|
Logistic Models | 2 | 2015 | 13605 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 2 | 2007 | 2582 | 0.050 |
Why?
|
Odds Ratio | 1 | 2015 | 9977 | 0.050 |
Why?
|
Immunity, Cellular | 2 | 2007 | 1681 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2017 | 15606 | 0.050 |
Why?
|
Lung | 1 | 2020 | 9734 | 0.050 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 2 | 2014 | 82 | 0.050 |
Why?
|
Self Report | 1 | 2013 | 3409 | 0.050 |
Why?
|
Antigens, CD | 2 | 2013 | 4149 | 0.050 |
Why?
|
Cerebrospinal Fluid | 1 | 2004 | 552 | 0.050 |
Why?
|
High Mobility Group Proteins | 1 | 2021 | 186 | 0.050 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2009 | 1906 | 0.050 |
Why?
|
Sulfonamides | 2 | 2021 | 1923 | 0.050 |
Why?
|
Surface-Active Agents | 1 | 2020 | 150 | 0.050 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 6572 | 0.050 |
Why?
|
Recurrence | 2 | 2016 | 8238 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 139 | 0.050 |
Why?
|
Massachusetts | 3 | 2020 | 8742 | 0.050 |
Why?
|
Respiratory Therapy | 1 | 2020 | 133 | 0.050 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2005 | 1016 | 0.050 |
Why?
|
Belgium | 1 | 2019 | 99 | 0.050 |
Why?
|
Valine | 1 | 2021 | 419 | 0.050 |
Why?
|
Phenotype | 4 | 2021 | 16302 | 0.050 |
Why?
|
Risk Assessment | 4 | 2022 | 23482 | 0.050 |
Why?
|
Glycerophosphates | 2 | 1995 | 47 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2015 | 39334 | 0.040 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2020 | 328 | 0.040 |
Why?
|
Cytokines | 2 | 2022 | 7190 | 0.040 |
Why?
|
Heroin Dependence | 1 | 2019 | 176 | 0.040 |
Why?
|
Cell Degranulation | 1 | 2019 | 295 | 0.040 |
Why?
|
Anilides | 1 | 2021 | 412 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2004 | 1249 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2007 | 6274 | 0.040 |
Why?
|
Wounds and Injuries | 1 | 2010 | 2412 | 0.040 |
Why?
|
Carbamates | 2 | 2010 | 199 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2020 | 1477 | 0.040 |
Why?
|
Anti-Retroviral Agents | 1 | 2007 | 1636 | 0.040 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 618 | 0.040 |
Why?
|
Mucins | 1 | 2020 | 552 | 0.040 |
Why?
|
Amino Acid Sequence | 5 | 2009 | 14154 | 0.040 |
Why?
|
Peptides | 2 | 2007 | 4386 | 0.040 |
Why?
|
Immunomodulation | 1 | 2021 | 529 | 0.040 |
Why?
|
Autopsy | 1 | 2020 | 988 | 0.040 |
Why?
|
Mental Disorders | 1 | 2016 | 6445 | 0.040 |
Why?
|
Brazil | 2 | 2011 | 1154 | 0.040 |
Why?
|
In Situ Hybridization | 1 | 2020 | 1984 | 0.040 |
Why?
|
Salmonella typhimurium | 2 | 1995 | 369 | 0.040 |
Why?
|
Pandemics | 3 | 2020 | 7306 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2010 | 5098 | 0.040 |
Why?
|
Glycosylation | 1 | 2019 | 1130 | 0.040 |
Why?
|
Retrospective Studies | 5 | 2020 | 72448 | 0.040 |
Why?
|
Health Personnel | 1 | 2009 | 3045 | 0.040 |
Why?
|
Central Nervous System Neoplasms | 1 | 2004 | 868 | 0.040 |
Why?
|
African Americans | 3 | 2020 | 4991 | 0.040 |
Why?
|
Prognosis | 3 | 2020 | 28991 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2017 | 322 | 0.030 |
Why?
|
Receptors, IgG | 1 | 2019 | 610 | 0.030 |
Why?
|
Protein Conformation | 2 | 2010 | 4028 | 0.030 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2014 | 24 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2020 | 58293 | 0.030 |
Why?
|
Immunity | 1 | 2020 | 975 | 0.030 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 87 | 0.030 |
Why?
|
Quinolines | 2 | 2010 | 735 | 0.030 |
Why?
|
Chemokines | 1 | 2019 | 965 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2686 | 0.030 |
Why?
|
Perforin | 1 | 2014 | 171 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2012 | 1531 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2009 | 4133 | 0.030 |
Why?
|
Evolution, Molecular | 3 | 2007 | 1934 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 9640 | 0.030 |
Why?
|
Genome, Viral | 2 | 2007 | 678 | 0.030 |
Why?
|
Amino Acids | 2 | 2010 | 1712 | 0.030 |
Why?
|
Amino Acid Substitution | 2 | 2010 | 1819 | 0.030 |
Why?
|
Tryptophan | 1 | 1994 | 453 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2017 | 702 | 0.030 |
Why?
|
Biopsy | 1 | 2004 | 6732 | 0.030 |
Why?
|
Molecular Sequence Data | 4 | 2007 | 18583 | 0.030 |
Why?
|
Time Factors | 2 | 2017 | 40889 | 0.030 |
Why?
|
Thiazoles | 2 | 2010 | 1515 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 5034 | 0.030 |
Why?
|
Weight Loss | 1 | 2022 | 2514 | 0.030 |
Why?
|
Prevalence | 1 | 2007 | 14877 | 0.020 |
Why?
|
Adolescent | 4 | 2019 | 85064 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1842 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 169 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2017 | 2767 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2014 | 5269 | 0.020 |
Why?
|
HIV Long-Term Survivors | 1 | 2010 | 125 | 0.020 |
Why?
|
Chromatin | 1 | 2021 | 2678 | 0.020 |
Why?
|
Point Mutation | 1 | 1995 | 1647 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 639 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 14439 | 0.020 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2009 | 50 | 0.020 |
Why?
|
Blood-Borne Pathogens | 1 | 2009 | 52 | 0.020 |
Why?
|
HIV Antigens | 1 | 2010 | 346 | 0.020 |
Why?
|
Needlestick Injuries | 1 | 2009 | 66 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1894 | 0.020 |
Why?
|
Phenylthiourea | 1 | 2008 | 11 | 0.020 |
Why?
|
Australia | 1 | 2012 | 1325 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1759 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3945 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1699 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1554 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 13215 | 0.020 |
Why?
|
Animals | 3 | 2009 | 169173 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2020 | 3630 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2021 | 11644 | 0.020 |
Why?
|
Earache | 1 | 2007 | 16 | 0.020 |
Why?
|
Netherlands | 1 | 2012 | 2089 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3423 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2017 | 1567 | 0.020 |
Why?
|
Pneumocephalus | 1 | 2007 | 33 | 0.020 |
Why?
|
Drosophila Proteins | 1 | 2017 | 1747 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15900 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3444 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 11192 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9374 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 2013 | 1474 | 0.020 |
Why?
|
Incidence | 3 | 2012 | 20761 | 0.020 |
Why?
|
Alleles | 2 | 2010 | 7095 | 0.020 |
Why?
|
Length of Stay | 1 | 2020 | 6272 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2007 | 381 | 0.020 |
Why?
|
Heart | 1 | 2020 | 4308 | 0.020 |
Why?
|
Genetic Variation | 2 | 2017 | 6659 | 0.020 |
Why?
|
Serotyping | 1 | 2007 | 377 | 0.020 |
Why?
|
Binding Sites | 2 | 2011 | 6210 | 0.020 |
Why?
|
Gene Products, nef | 1 | 2006 | 110 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2020 | 11664 | 0.020 |
Why?
|
Speech Disorders | 1 | 2007 | 178 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 11948 | 0.020 |
Why?
|
Unconsciousness | 1 | 2007 | 214 | 0.020 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 153 | 0.020 |
Why?
|
5' Untranslated Regions | 1 | 2007 | 260 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2015 | 1741 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2007 | 1120 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3148 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5746 | 0.020 |
Why?
|
Ultrasonography | 1 | 2019 | 5921 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2008 | 628 | 0.020 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2005 | 90 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3719 | 0.020 |
Why?
|
Intracranial Hypertension | 1 | 2007 | 181 | 0.020 |
Why?
|
Life Expectancy | 1 | 2012 | 1143 | 0.020 |
Why?
|
Chronic Disease | 3 | 2005 | 9028 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 13209 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3683 | 0.020 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2007 | 298 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2012 | 1923 | 0.020 |
Why?
|
Prospective Studies | 3 | 2016 | 51354 | 0.020 |
Why?
|
Models, Molecular | 2 | 2010 | 5450 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1758 | 0.020 |
Why?
|
Cross Reactions | 1 | 2006 | 876 | 0.020 |
Why?
|
Cytomegalovirus | 1 | 2008 | 691 | 0.020 |
Why?
|
Haplotypes | 1 | 2010 | 2883 | 0.020 |
Why?
|
HLA-DR Antigens | 1 | 2005 | 693 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2012 | 10600 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12490 | 0.010 |
Why?
|
Risk-Taking | 1 | 2009 | 997 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2004 | 342 | 0.010 |
Why?
|
Hepatitis C Antigens | 1 | 2002 | 35 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2007 | 2285 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2013 | 6092 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2007 | 1878 | 0.010 |
Why?
|
HIV Seropositivity | 1 | 2008 | 924 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2007 | 2919 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2012 | 1835 | 0.010 |
Why?
|
HLA-A2 Antigen | 1 | 2002 | 227 | 0.010 |
Why?
|
Serine | 2 | 1995 | 826 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 7983 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 9744 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9494 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10090 | 0.010 |
Why?
|
Brain | 1 | 2007 | 25189 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2007 | 1726 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4692 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2007 | 15185 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2975 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 24776 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2016 | 5032 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2009 | 1768 | 0.010 |
Why?
|
Health Care Costs | 1 | 2012 | 3165 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 27362 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 11942 | 0.010 |
Why?
|
Kinetics | 2 | 1995 | 6647 | 0.010 |
Why?
|
Indoles | 2 | 1995 | 1841 | 0.010 |
Why?
|
Radioisotope Dilution Technique | 1 | 1995 | 72 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2013 | 8028 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14887 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4303 | 0.010 |
Why?
|
Genetic Testing | 1 | 2008 | 3347 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 21804 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2007 | 4910 | 0.010 |
Why?
|
Base Sequence | 1 | 2007 | 13171 | 0.010 |
Why?
|
Cell Line | 1 | 2009 | 16559 | 0.010 |
Why?
|
Mathematics | 1 | 1995 | 747 | 0.010 |
Why?
|
Carbon Radioisotopes | 1 | 1995 | 612 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 7059 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2016 | 15101 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1995 | 1501 | 0.010 |
Why?
|
Catalysis | 1 | 1994 | 776 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1995 | 1776 | 0.010 |
Why?
|
Crystallography, X-Ray | 1 | 1994 | 1976 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1995 | 3197 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2002 | 5109 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2005 | 19892 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 20337 | 0.000 |
Why?
|
Models, Theoretical | 1 | 1995 | 3585 | 0.000 |
Why?
|